Hello, and welcome to the Transgene First-Half 2023 Financial Results and Business Update Call. Please note this conference is being recorded and for the duration of the call your lines will be on ...
TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, ...
Strasbourg, France, February 4, 2026, 5:45 p.m. CET - Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, todayannounce ...
PARIS, 19 mars (Reuters) - Transgene a creusé sa perte en 2011 mais la société de biotechnologie dit aborder avec "confiance" les 18 prochains mois, au cours desquels elle devrait publier des ...
Transgene SA has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I trial of TG-6050, a ...
Transgene a annoncé la nomination de deux nouveaux conseillers scientifiques de premier plan au sein de son Conseil Scientifique, le Professeur Antoine Italiano, MD, PhD, et le Professeur Ignacio ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Transgene's intravenous IL-12-armed oncolytic virus TG-6050 cleared to enter clinic trials in France
Transgene SA has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I trial of TG-6050, a ...
13/02 Transgene Biotek Limited publie ses résultats financiers pour le troisième trimestre et les neuf mois clos le 31 décembre 2025 CI 03/02 Transgene Biotek reçoit une ordonnance de la SEBI gelant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results